Delaware law has long recognized a director’s duty of oversight. The well-established doctrine, first articulated in 1996 in In Re: Caremark International Inc. Derivative Litigation, was recently expanded to officers in In re...more
On October 1, 2019, the Court of Chancery rendered an opinion in In re Clovis Oncology, Inc. Derivative Litigation, denying a motion to dismiss a Caremark claim for breach of fiduciary duty and reinforcing a director’s duty...more
10/15/2019
/ Board of Directors ,
Breach of Duty ,
CFOs ,
Clinical Trials ,
Compliance ,
Corporate Governance ,
Directors ,
Duty of Loyalty ,
Fiduciary Duty ,
Food and Drug Administration (FDA) ,
Motion to Dismiss ,
Oversight Duties ,
Prescription Drugs